NEW YORK – Revenue losses due to patent expirations, an increasingly complicated regulatory landscape and erratic results in getting drugs to market are key dynamics forcing biopharmas to take a look in the mirror and acknowledge the need for change, according to a panel at the New York Biotechnology Association 21st annual meeting this week.